Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Clinical efficacy of idebenone in stroke patients with mild cognitive impairment, and its effect on regional homogeneity of resting-state functional magnetic resonance imaging of the brain

Xiaoyu Zhang^1-3, Juan Li^1,2

¹Center on Aging Psychology, CAS Key Laboratory of Mental Health, Institute of Psychology, Chinese Academy of Sciences, Beijing, China; ²Department of Psychology, University of Chinese Academy of Sciences, Beijing, China; ³China Rehabilitation Research Center Beijing Boai Hospital, Rehabilitation School of Capital Medical University, Beijing, China.

For correspondence:- Juan Li Email: gongnliju17624@163.com Tel:+8613381083366

Accepted: 30 June 2022 Published: 31 July 2022

Citation: Zhang X, Li J. Clinical efficacy of idebenone in stroke patients with mild cognitive impairment, and its effect on regional homogeneity of resting-state functional magnetic resonance imaging of the brain. Trop J Pharm Res 2022; 21(7):1557-1564 doi: 10.4314/tjpr.v21i7.28

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To evaluate the clinical efficacy of Idebenone in stroke patients with mild cognitive impairment, and its effect on regional homogeneity (ReHo) of resting-state functional magnetic resonance imaging (rs-fMRI) of the brain.

Methods: One hundred and twenty stroke patients with mild cognitive impairment who were admitted to the Department of Neurology of the China Rehabilitation Research Center Beijing Boai Hospital from January 2018 to January 2020 were enrolled in this study. The patients were randomly divided into control group and study group. Control group was treated with nimodipine, while the study group received a combination of nimodipine and idebenone.

Results: Clinical efficacy was higher in the study group than in the control group (p < 0.05). Scores on Montreal cognitive assessment (MoCA), mini-mental state examination (MMSE), and activity of daily living scale (ADL) were significantly elevated (p < 0.05) in both groups after treatment, but scores for MoCA and ADL were significantly higher in the study group than in the control group (p < 0.05). After 6 months of treatment, there were significantly more patients with improved clinical dementia rating (CDR) in the study group than in the control group (p < 0.05).

Conclusion: The use of idebenone and nimodipine for treatment of stroke patients with cognitive dysfunction leads to significant improvement in clinical outcomes, and enhancement of cognitive function and quality of life, due to improved brain function in the precuneus. However, the mechanism involved in the combination therapy-induced enhancement of cognitive function requires further investigation.

Keywords: Stroke, Cognitive dysfunction, Resting-state functional magnetic resonance imaging of brain, Regional homogeneity, Quality of life